| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2015: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2014: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2013: ¥2,990,000 (Direct Cost: ¥2,300,000、Indirect Cost: ¥690,000)
|
|---|
| Outline of Final Research Achievements |
Patients with amyopathic dermatomyositis (ADM) sometimes develop rapidly progressive interstitial lung disease (ILD). Although anti-CADM-140/MDA5 antibody titer could predict the course of ADM-ILD, it is not clear how this antibody is involved in the pathogenesis of the disease. We retrospectively collected clinical records and preserved serum before treatment of consecutive patients with ADM-ILD since 2000 to 2014. Of 13 patients enrolled, four did not respond to therapy and died. The mean anti-CADM-140/MDA5 antibody titer was significantly higher in patients who did not responded (p<0.05). Then we measured serum cytokine/growth factor (GF) protein concentration using a multiplex immunoassay system. Relationship analyses between the antibody titer and each cytokine/GF protein concentration revealed that Spearman's rank correlation coefficients were more than 0.4 in 13 cytokine/GF proteins. The strongest correlation was found between the antibody titer and CX3CL1 (r=0.8897).
|
